{"id":"W2593142478","doi":"10.1158/1538-7445.sabcs16-p2-08-02","title":"Abstract P2-08-02: Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Metastatic breast cancer; Breast cancer; Progression-free survival; Randomized controlled trial; Cancer; Estrogen receptor; Tamoxifen; Confidence interval; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002538489,0.0004959966,0.001879093,0.0003777785,0.000443764,0.000100618,0.0008775282,0.0002610248,0.0003054218],"category_scores_gemma":[0.001620518,0.0004026135,0.0004046469,0.0003445363,0.001437324,0.0005528295,0.0002781275,0.0009714516,0.000007330153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009562729,"about_ca_system_score_gemma":0.001385605,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007172445,"about_ca_topic_score_gemma":0.001541609,"domain_scores_codex":[0.9941031,0.0004437886,0.001359008,0.001113321,0.001736371,0.001244431],"domain_scores_gemma":[0.9940842,0.001447574,0.0009313138,0.001703917,0.001358869,0.0004741219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7204437,0.0009611658,0.0001377955,0.0001216987,0.0003451331,0.00004803518,0.0009899647,0.0000371863,0.08671026,0.00003497141,0.0003248889,0.1898452],"study_design_scores_gemma":[0.9306591,0.002658262,0.01033067,0.00238008,0.000108681,0.00000543622,0.0006619357,0.0001135661,0.05064107,0.0005314855,0.001493085,0.0004166702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9682123,0.003519246,0.0001283547,0.006949286,0.0008730391,0.008442379,0.01153651,0.00005192475,0.0002869568],"genre_scores_gemma":[0.989136,0.001889905,0.001404345,0.00005288796,0.001120269,0.005777292,0.0003719761,0.0001132416,0.000134049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2102153,"threshold_uncertainty_score":0.9998426,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04892518589419236,"score_gpt":0.4243854917778676,"score_spread":0.3754603058836752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}